July 19, 2016 / 10:22 PM / a year ago

BRIEF-Valeant and Progenics announce FDA approvals for relistor

July 19 (Reuters) - Progenics Pharmaceuticals Inc :

* Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016

* Valeant and Progenics announce FDA approves relistor tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain

* FDA has approved relistor (methylnaltrexone bromide) tablets for treatment of opioid-induced constipation Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below